Volume | 2,514,063 |
|
|||||
News | - | ||||||
Day High | 11.10 | Low High |
|||||
Day Low | 10.62 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dynavax Technologies Corp | DVAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.06 | 10.62 | 11.10 | 10.73 | 11.01 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
17,446 | 2,514,063 | $ 10.89 | $ 27,385,055 | - | 10.48 - 15.15 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:45:47 | 50 | $ 10.97 | USD |
Dynavax Technologies Corp Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.4B | 130.61M | - | 232.28M | -6.39M | -0.05 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dynavax Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVAX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.87 | 12.06 | 10.48 | 11.45 | 2,534,388 | -0.89 | -7.50% |
1 Month | 12.01 | 12.08 | 10.48 | 11.56 | 2,428,745 | -1.03 | -8.58% |
3 Months | 12.43 | 13.265 | 10.48 | 12.06 | 2,057,619 | -1.45 | -11.67% |
6 Months | 13.10 | 15.01 | 10.48 | 12.82 | 1,905,486 | -2.12 | -16.18% |
1 Year | 10.90 | 15.15 | 10.48 | 13.18 | 1,779,347 | 0.08 | 0.73% |
3 Years | 9.26 | 21.39 | 7.09 | 12.99 | 2,179,016 | 1.72 | 18.57% |
5 Years | 7.68 | 21.39 | 1.80 | 9.84 | 2,633,816 | 3.30 | 42.97% |
Dynavax Technologies Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. |